CATX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 45 cases where CATX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CATX's RSI Oscillator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where CATX advanced for three days, in 212 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CATX as a result. In 83 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CATX turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CATX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CATX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.811) is normal, around the industry mean (2.874). P/E Ratio (-1.729) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. CATX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CATX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The 10-day moving average for MTD crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for MTD just turned positive on September 17, 2026. Looking at past instances where MTD's MACD turned positive, the stock continued to rise in 31 of 48 cases over the following month. The odds of a continued upward trend are 65%.
Following a +3.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTD advanced for three days, in 193 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 131 of 225 cases where MTD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
MTD broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 3 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. MTD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTD's P/B Ratio (2621.863) is very high in comparison to the industry average of (66.046). P/E Ratio (37.723) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (2.869) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.798) is also within normal values, averaging (9.775).
CATX | MTD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 34 Fair valued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 87 | |
SMR RATING 1..100 | 97 | 3 | |
PRICE GROWTH RATING 1..100 | 83 | 6 | |
P/E GROWTH RATING 1..100 | 19 | 31 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CATX's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for MTD (99) in the Medical Specialties industry. This means that CATX’s stock grew somewhat faster than MTD’s over the last 12 months.
MTD's Profit vs Risk Rating (87) in the Medical Specialties industry is in the same range as CATX (100) in the Biotechnology industry. This means that MTD’s stock grew similarly to CATX’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is significantly better than the same rating for CATX (97) in the Biotechnology industry. This means that MTD’s stock grew significantly faster than CATX’s over the last 12 months.
MTD's Price Growth Rating (6) in the Medical Specialties industry is significantly better than the same rating for CATX (83) in the Biotechnology industry. This means that MTD’s stock grew significantly faster than CATX’s over the last 12 months.
CATX's P/E Growth Rating (19) in the Biotechnology industry is in the same range as MTD (31) in the Medical Specialties industry. This means that CATX’s stock grew similarly to MTD’s over the last 12 months.
| CATX | MTD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 90% | N/A |
| MACD ODDS (%) | 1 day ago 90% | 4 days ago 65% |
| TrendWeek ODDS (%) | 1 day ago 89% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 60% |
| Advances ODDS (%) | 3 days ago 80% | 1 day ago 61% |
| Declines ODDS (%) | 9 days ago 87% | 22 days ago 66% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 61% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 58% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CATX’s FA Score shows that 1 FA rating(s) are green while MTD’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CATX’s TA Score shows that 4 TA indicator(s) are bullish while MTD’s TA Score has 4 bullish TA indicator(s).
CATX (@Medical/Nursing Services) experienced а -3.42% price change this week, while MTD (@Medical Specialties) price change was +2.78% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.29%. For the same industry, the average monthly price growth was -6.63%, and the average quarterly price growth was +42.53%.
CATX is expected to report earnings on Nov 09, 2026.
MTD is expected to report earnings on Nov 05, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.29% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VGLT | 52.39 | 0.91 | +1.77% |
| Vanguard Long-Term Treasury ETF (VGLT) | |||
| WDI | 11.62 | -0.02 | -0.17% |
| Western Asset Diversified Income Fund | |||
| QBUF | 30.34 | -0.39 | -1.27% |
| Innovator Nasdaq-100 10 Buffer ETF Quarterly (QBUF) | |||
| EMCR | 40.09 | -1.19 | -2.88% |
| Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF (EMCR) | |||
| KLAG | 15.17 | -3.66 | -19.42% |
| Leverage Shares 2x Long KLAC Daily ETF (KLAG) | |||